|
 |
 |
To
Develop and Produce the Next Generation of Cancer Vaccines
and Epoch-making Immunotherapeutics
|
|
|
|
| Protein
Vaccines for Cancer |
- ImmunoFrontier's technology is based on a unique
delivery system utilizing a nano-particle of cholesteryl
hydrophobized pullulan which includes a tumor antigen
(WO98/09650, US6656481).
- ImmunoFrontier's protein vaccines for cancer are
superior to conventional peptide vaccines because
almost whole protein of a tumor antigen bearing
various epitopes is utilized, and capable of activating
not only killer T cells but also helper T cells
and coping with a wider range of HLA types (Multiepitope
and Polyvalent).
- Prof. Shiku began the multi-central clinical research
on the protein vaccines for cancer in October 2004
as a part of the Cancer Translational Research Program
of the Ministry of Education, Culture, Sports, Science
and Technology, collaborating with other four groups
of Hokkaido University, Aichi Cancer Center, Okayama
University and Kyushu University. ImmunoFrontier
is going to develop the outcome of the research
toward the pharmaceutical business.
|
| DNA
Vaccines for Cancer |
- ImmunoFrontier's second technology is used for
the development of DNA vaccines. Multifunctional
and polyvalent DNA vaccines consisting of expression
plasmids of a tumor and a SEREX antigens and a cytokine
are able to mediate powerful anti-tumor immunity
(WO03/000894, WO2004/058299).
- A clear pharmacological effect was demonstrated
in an experiment using tumor-bearing mice (Proc.
Natl. Acad. Sci. USA 98:14571-14576, 2001).
|
| Novel
Immunotherapeutics |
- Based on the unique mechanism found by Prof. Shiku
and his colleagues, ImmunoFrontier aims at inventing
epoch-making therapy for intractable immune diseases
such as rheumatoid arthritis and allergies. (Proc.
Natl. Acad. Sci. USA 100:10902-10906,2003; WO2004/024174
).
- Remarkable therapeutic effects were shown for
several immune diseases by experiments using disease
model mice (Patent applied).
|
|
|
|
|
|
|
|
|
|
|
|
